Across these AAIC presentations, we are showing how AC Immune’s Morphomer®-based small molecule approach has generated differentiated therapeutic and imaging assets. Our first-in-class TDP-43 PET tracer has generated encouraging early human imaging data in FTD and ALS; our novel brain-penetrant NLRP3 inhibitor is in Phase 1 with a profile supporting an orally delivered CNS therapy; and our alpha-synuclein Morphomer® program demonstrates potent, brain-penetrant inhibition of pathology with in vivo neuroprotective effects. Together, these data reinforce the opportunity to build biomarker-led therapeutic programs for major neurodegenerative diseases.

Oral Presentation

Discovery and initial clinical evaluation of [18F]ACI-19626, a first-in-class TDP-43 PET tracer

Presenter: Dr. Tamara Seredinina

Session: Developing Topics in ADRD Diagnostics

Date/Time: July 15, 8:00 – 8:45 AM BST (GMT+1)

Location: Hall S11

Poster Presentations

Novel potent brain penetrant NLRP3 inhibitor ACI-19764 demonstrates efficacy in models of neuroinflammation

Presenter: Dr. Chantal Bazenet

Session: Drug Development, Human

Date/Time: July 12, 7:30 AM – 4:15 PM BST (GMT+1)

Location: Exhibit Hall (# Sunday-0177)

Development of an aggregation inhibitor targeting alpha-synuclein pathology

Presenter: Dr. Francesca Capotosti

Session: Drug Development, Nonhuman

Date/Time: July 14, 7:30 AM – 4:15 PM BST (GMT+1)

Location: Exhibit Hall (# Tuesday-0074)